Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas

Journal of B.U.ON.

Volumn 16, Issue 2, 2011, Pages 282-289

  Soritau, O ^a   Tomuleasa, Ciprian ^a   Aldea, M ^a   Petrushev, B ^a   Susman, S ^b   Gheban, D ^b   Ioani, H ^b   Cosis, A ^b   Brie, I ^a   Irimie, A ^a   Kacso, G ^a   Florian, I S ^b  

^a THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^b Emergency University Clinical Hospital   (Romania)

Author keywords

Adjuvant chemotherapy; Malignant gliomas; Metformin; Primary tumor cell culture; Temozolomide

Indexed keywords

EPIDERMAL GROWTH FACTOR; METFORMIN; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL PROLIFERATION; CHEMORADIOTHERAPY; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; GLIOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MALE; MONOTHERAPY; PHENOTYPE; POLYMERASE CHAIN REACTION; TUMOR CELL; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; FEMALE; GLIOMA; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOENZYME TECHNIQUES; MALE; METFORMIN; MIDDLE AGED; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; WORLD HEALTH ORGANIZATION;

EID: 79960245510     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Benin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumors in adults. Lancet 2003; 361: 323-331.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
3. Stupp R, Hottinger AF, van den Bent MJ et al. Frequently asked questions in the medical management of high-grade gliomas: a short guide with practical answers. ESMO educational book. Ann Oncol 2008; 19(Suppl 7): vii209-vii216.
4. Stupp R, Tonn JC, Brada M, Pentheroudakis G. High-grade malignant gliomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5):v190-v193.
5. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996. (Pubitemid 40349501)
6. Tomuleasa C, Soritau O, Rus-Ciuca D et al. Functional and molecular characterization of glioblastoma multiforme-derived cancer stem cells. J BUON 2010; 15: 583-591.
7. Tomuleasa C, Soritau O, Rus-Ciuca D et al. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis 2010; 19: 61-67.
8. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006; 355: 1253-1261. (Pubitemid 44427449)
9. Cheshier SH, Kalani MY, Lim M, Ailles L, Huhn SH, Weissman IL. A neurosurgeon's guide to stem cells, cancer stem cells, and brain tumor stem cells. Neurosurgery 2009; 65: 237-249.
10. Tomuleasa C, Kacso G, Soritau O, Susman S, Irimie A, Virag P. Cellular interactions in prostate cancer genesis and dissemination. Looking beyond the obvious. Rom J Morphol Embryol 2010; 51: 427-435.
11. Stupp R, Hegi M, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
12. Vasquez-Martin A, Oliveras-Ferraros C, Cufi S et al. The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncol Rep 2011; 25: 135-140.
13. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33: 322-326.
14. Home PD, Kahn SE, Jones NP et al. Experience of malignancies with oral glucose-lowering drugs in the randomized controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010; 53: 1838-1845.
15. Miebach S, Grau S, Hummel V, Rieckmann P, Tonn JC, Goldbrunner RH. Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades. J Neurooncol 2006; 76: 3948.
16. Tomuleasa C, Soritau O, Kacso G et al. Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable malignant gliomas. J BUON 2010; 15: 758-762.
17. Wen PY, McDonald DR, Reardon RA et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963-1972.
18. Server A, Kulle B, Gadmar OB, Josefsen R, Kumar T, Nakstad PH. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas. Eur J Radiol 2010; in press.
19. Gerster ER, Batchelor TT. Imaging and response criteria in gliomas. Curr Opin Oncol 2010; 22: 598-603.
20. Grossman SA, Ye X, Piantadosi S et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010; 16: 2443-2449.
21. Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 2010; 9: 717-726.
22. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003. (Pubitemid 40349502)
23. Blought MD, Westgate MR, Beauchamp D et al. Sensitivity to temozolomide in brain tumor initiating cells. Neuro Oncol 2010; 12: 756-770.
24. Erreni M, Solinas G, Brescia P et al. Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer 2010; 46: 3383-3392.
25. Sato A, Sakurada K, Kumabe T et al. Association of stem cell marker CD 133 expression with dissemination of glioblastomas. Neurosurg Rev 2010; 33: 175-184.
26. Bleau AM, Huse JS, Holland EC. The ABCG2 resistance network of glioblastoma. Cell Cycle 2009; 8: 2937-2945.
27. Evers P, Lee PP, DeMarco J et al. Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma. BMC Cancer 2010; 10: 384-391.
28. Rodriguez Salas N, Gonzalez Gonzales E, Gamallo Amat C. Breast cancer stem cell hypothesis: clinical relevance (answering breast cancer clinical features). Clin Transi Oncol 2010; 12: 395400.
29. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69: 7507-7511.
30. Wang R, Chadalavada K, Wilshire J et al. Glioblastoma stem-like cells give rise to tumor endothelium. Nature 2010; 468: 829-833.
31. Ricci-Vitiani L, Pallini R, Biffoni M et al. Tumor vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824-828.